Top

Published in:

01-11-2014 | Original Article

Chimeric influenza-virus-like particles containing the porcine reproductive and respiratory syndrome virus GP5 protein and the influenza virus HA and M1 proteins

Authors: Chunyi Xue, Wei Wang, Qiliang Liu, Zhongwei Miao, Kang Liu, Huifang Shen, Lishan Lv, Xiaoming Li, Xiaochun Chen, Yongchang Cao

Published in: Archives of Virology | Issue 11/2014

Abstract

Both porcine reproductive and respiratory syndrome and swine influenza are acute, highly contagious swine diseases. These diseases pose severe threats for the swine industry and cause heavy economic losses worldwide. In this study, we have developed a chimeric virus-like particle (VLP) vaccine candidate for porcine reproductive and respiratory syndrome virus (PRRSV) and H3N2 influenza virus and investigated its immunogenicity in mice. The HA and M1 proteins from the H3N2 influenza virus and the PRRSV GP5 protein fused to the cytoplasmic and transmembrane domains of the NA protein were both incorporated into the chimeric VLPs. Analysis of the immune responses showed that the chimeric VLPs elicited serum antibodies specific for both PRRSV GP5 and the H3N2 HA protein, and they stimulated cellular immune responses compared to the responses to equivalent amounts of inactivated viruses. Taken together, the results suggested that the chimeric VLP vaccine represents a potential strategy for the development of a safe and effective vaccine to control PRRSV and H3N2 influenza virus.

Albina E (1997) Epidemiology of porcine reproductive and respiratory syndrome (PRRS): an overview. Vet Microbiol 55(1–4):309–316PubMedCrossRef

Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF (2008) Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 38(1):114–126PubMedCrossRef

Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3(1):e1501PubMedCrossRefPubMedCentral

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM (2007) Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19):3871–3878PubMedCrossRef

Cavanagh D (1997) Nidovirales: a new order comprising Coronaviridae and Arteriviridae. Arch Virol 142(3):629–633PubMed

Chichester JA, Haaheim LR, Yusibov V (2009) Using plant cells as influenza vaccine substrates. Expert Rev Vaccines 8(4):493–498PubMedCrossRef

Choi YK, Goyal SM, Joo HS (2003) Retrospective analysis of etiologic agents associated with respiratory diseases in pigs. Can Vet J 44(9):735–737PubMedPubMedCentral

Crevar CJ, Ross TM (2008) Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 5:131PubMedCrossRefPubMedCentral

Crisci E, Fraile L, Moreno N, Blanco E, Cabezon R, Costa C, Mussa T, Baratelli M, Martinez-Orellana P, Ganges L, Martinez J, Barcena J, Montoya M (2012) Chimeric calicivirus-like particles elicit specific immune responses in pigs. Vaccine 30(14):2427–2439PubMedCrossRef

10.

Daniels PS, Jeffries S, Yates P, Schild GC, Rogers GN, Paulson JC, Wharton SA, Douglas AR, Skehel JJ, Wiley DC (1987) The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J 6(5):1459–1465PubMedPubMedCentral

11.

Hanumantha RN, Baji BP, Rajendra L, Sriraman R, Pang YY, Schiller JT, Srinivasan VA (2011) Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles. Vaccine 29(43):7326–7334CrossRef

12.

Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C (2009) Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27(4):530–541PubMedCrossRef

13.

Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, Donatelli I, Kida H, Paulson JC, Webster RG, Kawaoka Y (1998) Molecular basis for the generation in pigs of influenza a viruses with pandemic potential. J Virol 72(9):7367–7373PubMedPubMedCentral

14.

Kang SM, Pushko P, Bright RA, Smith G, Compans RW (2009) Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 333:269–289PubMed

15.

Kang SM, Song JM, Quan FS, Compans RW (2009) Influenza vaccines based on virus-like particles. Virus Res 143(2):140–146PubMedCrossRefPubMedCentral

16.

Koho T, Huhti L, Blazevic V, Nurminen K, Butcher SJ, Laurinmaki P, Kalkkinen N, Ronnholm G, Vesikari T, Hytonen VP, Kulomaa MS (2012) Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. J Virol Methods 179(1):1–7PubMedCrossRef

17.

Latham T, Galarza JM (2001) Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 75(13):6154–6165PubMedCrossRefPubMedCentral

18.

Li Y, Xue C, Wang L, Chen X, Chen F, Cao Y (2010) Genomic analysis of two Chinese strains of porcine reproductive and respiratory syndrome viruses with different virulence. Virus Genes 40(3):374–381PubMedCrossRef

19.

Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL (2012) Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30(7):1305–1312PubMedCrossRef

20.

Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G (2011) Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 29(38):6606–6613PubMedCrossRefPubMedCentral

21.

McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG (2011) Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 85(1):366–377PubMedCrossRefPubMedCentral

22.

McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, Morrison TG (2010) Assembly and biological and immunological properties of Newcastle disease virus-like particles. J Virol 84(9):4513–4523PubMedCrossRefPubMedCentral

23.

Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG (2010) Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 84(2):1110–1123PubMedCrossRefPubMedCentral

24.

Neumann EJ, Kliebenstein JB, Johnson CD, Mabry JW, Bush EJ, Seitzinger AH, Green AL, Zimmerman JJ (2005) Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. J Am Vet Med Assoc 227(3):385–392PubMedCrossRef

25.

Noad R, Roy P (2003) Virus-like particles as immunogens. Trends Microbiol 11(9):438–444PubMedCrossRef

26.

Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, Green KY (2012) Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30(24):3580–3586PubMedCrossRefPubMedCentral

27.

Pejsak Z, Stadejek T, Markowska-Daniel I (1997) Clinical signs and economic losses caused by porcine reproductive and respiratory syndrome virus in a large breeding farm. Vet Microbiol 55(1–4):317–322PubMedCrossRef

28.

Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM (2009) Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 83(11):5726–5734PubMedCrossRefPubMedCentral

29.

Puranaveja S, Poolperm P, Lertwatcharasarakul P, Kesdaengsakonwut S, Boonsoongnern A, Urairong K, Kitikoon P, Choojai P, Kedkovid R, Teankum K, Thanawongnuwech R (2009) Chinese-like strain of porcine epidemic diarrhea virus, Thailand. Emerg Infect Dis 15(7):1112–1115PubMedCrossRefPubMedCentral

30.

Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM (2010) Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28(30):4771–4776PubMedCrossRef

31.

Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM (2011) Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29(35):5911–5918PubMedCrossRef

32.

Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G (2005) Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50):5751–5759PubMedCrossRef

33.

Quan FS, Huang C, Compans RW, Kang SM (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81(7):3514–3524PubMedCrossRefPubMedCentral

34.

Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM (2008) A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26(26):3352–3361PubMedCrossRef

35.

Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA (2009) A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 4(6):e6032PubMedCrossRefPubMedCentral

36.

Rossow KD (1998) Porcine reproductive and respiratory syndrome. Vet Pathol 35(1):1–20PubMedCrossRef

37.

Thacker EL (2001) Immunology of the porcine respiratory disease complex. Vet Clin North Am Food Anim Pract 17(3):551–565PubMed

38.

Wang W, Chen X, Xue C, Du Y, Lv L, Liu Q, Li X, Ma Y, Shen H, Cao Y (2012) Production and immunogenicity of chimeric virus-like particles containing porcine reproductive and respiratory syndrome virus GP5 protein. Vaccine 30(49):7072–7077PubMedCrossRef

39.

Wang YS, Ouyang W, Liu XJ, He KW, Yu SQ, Zhang HB, Fan HJ, Lu CP (2012) Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV. Vaccine 30(12):2125–2130PubMedCrossRef

40.

Wei HJ, Chang W, Lin SC, Liu WC, Chang DK, Chong P, Wu SC (2011) Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine 29(41):7163–7172PubMedCrossRef

41.

Zhang L, Parham NJ, Zhang F, Aasa-Chapman M, Gould EA, Zhang H (2012) Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis. Vaccine 30(13):2301–2308PubMedCrossRef

Title: Chimeric influenza-virus-like particles containing the porcine reproductive and respiratory syndrome virus GP5 protein and the influenza virus HA and M1 proteins
Authors: Chunyi Xue
Wei Wang
Qiliang Liu
Zhongwei Miao
Kang Liu
Huifang Shen
Lishan Lv
Xiaoming Li
Xiaochun Chen
Yongchang Cao
Publication date: 01-11-2014
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 11/2014
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-014-2178-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2014

CLEC4M-positive and CD81-negative Huh7 cells are not susceptible to JFH-1 HCVcc infection but mediate transinfection

Genomic characterization of coxsackievirus type A24 strains associated with acute flaccid paralysis and rarely identified Hopkins syndrome

Genomic and phylogenetic characterization of Shuni virus

Characterization and genome sequence of Dev2, a new T7-like bacteriophage infecting Cronobacter turicensis

Experimental infection of cattle and goats with a foot-and-mouth disease virus isolate from the 2010 epidemic in Japan

Luteovirus: insights into pathogenicity

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials